A drug candidate for Alzheimer’s and Huntington’s disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides

Abstract Background Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. Objectives To evaluate whether PBT2/zinc may sensitize M...

Full description

Saved in:
Bibliographic Details
Published inJournal of antimicrobial chemotherapy Vol. 76; no. 11; pp. 2850 - 2853
Main Authors Jen, Freda E -C, El-Deeb, Ibrahim M, Zalucki, Yaramah M, Edwards, Jennifer L, Walker, Mark J, von Itzstein, Mark, Jennings, Michael P
Format Journal Article
LanguageEnglish
Published England Oxford University Press 11.10.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. Objectives To evaluate whether PBT2/zinc may sensitize MDR N. gonorrhoeae to natural cationic antimicrobial peptides. Methods MDR strains that contain differing resistance mechanisms against numerous antibiotics were tested in MIC assays. MIC assays were performed using the broth microdilution method according to CLSI guidelines in a microtitre plate. Serially diluted LL-37 or PG-1 was tested in combination with a sub-inhibitory concentration of PBT2/zinc. Serially diluted tetracycline was also tested with sub-inhibitory concentrations of PBT2/zinc and LL-37. SWATH-MS proteomic analysis of N. gonorrhoeae treated with PBT2/zinc, LL-37 and/or tetracycline was performed to determine the mechanism(s) of N. gonorrhoeae susceptibility to antibiotics and peptides. Results Sub-inhibitory concentrations of LL-37 and PBT2/zinc synergized to render strain WHO-Z susceptible to tetracycline, whereas the killing effect of PG-1 and PBT2/zinc was additive. SWATH-MS proteomic analysis suggested that PBT2/zinc most likely leads to a loss of membrane integrity and increased protein misfolding and, in turn, results in bacterial death. Conclusions Here we show that PBT2, a candidate Alzheimer’s and Huntington’s disease drug, can be repurposed to render MDR N. gonorrhoeae more susceptible to the endogenous antimicrobial peptides LL-37 and PG-1. In the presence of LL-37, PBT2/zinc can synergize with tetracycline to restore tetracycline susceptibility to gonococci resistant to this antibiotic.
AbstractList Abstract Background Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. Objectives To evaluate whether PBT2/zinc may sensitize MDR N. gonorrhoeae to natural cationic antimicrobial peptides. Methods MDR strains that contain differing resistance mechanisms against numerous antibiotics were tested in MIC assays. MIC assays were performed using the broth microdilution method according to CLSI guidelines in a microtitre plate. Serially diluted LL-37 or PG-1 was tested in combination with a sub-inhibitory concentration of PBT2/zinc. Serially diluted tetracycline was also tested with sub-inhibitory concentrations of PBT2/zinc and LL-37. SWATH-MS proteomic analysis of N. gonorrhoeae treated with PBT2/zinc, LL-37 and/or tetracycline was performed to determine the mechanism(s) of N. gonorrhoeae susceptibility to antibiotics and peptides. Results Sub-inhibitory concentrations of LL-37 and PBT2/zinc synergized to render strain WHO-Z susceptible to tetracycline, whereas the killing effect of PG-1 and PBT2/zinc was additive. SWATH-MS proteomic analysis suggested that PBT2/zinc most likely leads to a loss of membrane integrity and increased protein misfolding and, in turn, results in bacterial death. Conclusions Here we show that PBT2, a candidate Alzheimer’s and Huntington’s disease drug, can be repurposed to render MDR N. gonorrhoeae more susceptible to the endogenous antimicrobial peptides LL-37 and PG-1. In the presence of LL-37, PBT2/zinc can synergize with tetracycline to restore tetracycline susceptibility to gonococci resistant to this antibiotic.
BACKGROUNDNeisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. OBJECTIVESTo evaluate whether PBT2/zinc may sensitize MDR N. gonorrhoeae to natural cationic antimicrobial peptides. METHODSMDR strains that contain differing resistance mechanisms against numerous antibiotics were tested in MIC assays. MIC assays were performed using the broth microdilution method according to CLSI guidelines in a microtitre plate. Serially diluted LL-37 or PG-1 was tested in combination with a sub-inhibitory concentration of PBT2/zinc. Serially diluted tetracycline was also tested with sub-inhibitory concentrations of PBT2/zinc and LL-37. SWATH-MS proteomic analysis of N. gonorrhoeae treated with PBT2/zinc, LL-37 and/or tetracycline was performed to determine the mechanism(s) of N. gonorrhoeae susceptibility to antibiotics and peptides. RESULTSSub-inhibitory concentrations of LL-37 and PBT2/zinc synergized to render strain WHO-Z susceptible to tetracycline, whereas the killing effect of PG-1 and PBT2/zinc was additive. SWATH-MS proteomic analysis suggested that PBT2/zinc most likely leads to a loss of membrane integrity and increased protein misfolding and, in turn, results in bacterial death. CONCLUSIONSHere we show that PBT2, a candidate Alzheimer's and Huntington's disease drug, can be repurposed to render MDR N. gonorrhoeae more susceptible to the endogenous antimicrobial peptides LL-37 and PG-1. In the presence of LL-37, PBT2/zinc can synergize with tetracycline to restore tetracycline susceptibility to gonococci resistant to this antibiotic.
Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N. gonorrhoeae strains represents an immediate public health threat. To evaluate whether PBT2/zinc may sensitize MDR N. gonorrhoeae to natural cationic antimicrobial peptides. MDR strains that contain differing resistance mechanisms against numerous antibiotics were tested in MIC assays. MIC assays were performed using the broth microdilution method according to CLSI guidelines in a microtitre plate. Serially diluted LL-37 or PG-1 was tested in combination with a sub-inhibitory concentration of PBT2/zinc. Serially diluted tetracycline was also tested with sub-inhibitory concentrations of PBT2/zinc and LL-37. SWATH-MS proteomic analysis of N. gonorrhoeae treated with PBT2/zinc, LL-37 and/or tetracycline was performed to determine the mechanism(s) of N. gonorrhoeae susceptibility to antibiotics and peptides. Sub-inhibitory concentrations of LL-37 and PBT2/zinc synergized to render strain WHO-Z susceptible to tetracycline, whereas the killing effect of PG-1 and PBT2/zinc was additive. SWATH-MS proteomic analysis suggested that PBT2/zinc most likely leads to a loss of membrane integrity and increased protein misfolding and, in turn, results in bacterial death. Here we show that PBT2, a candidate Alzheimer's and Huntington's disease drug, can be repurposed to render MDR N. gonorrhoeae more susceptible to the endogenous antimicrobial peptides LL-37 and PG-1. In the presence of LL-37, PBT2/zinc can synergize with tetracycline to restore tetracycline susceptibility to gonococci resistant to this antibiotic.
Author Edwards, Jennifer L
Zalucki, Yaramah M
Jen, Freda E -C
von Itzstein, Mark
Jennings, Michael P
Walker, Mark J
El-Deeb, Ibrahim M
Author_xml – sequence: 1
  givenname: Freda E -C
  surname: Jen
  fullname: Jen, Freda E -C
  email: m.jennings@griffith.edu.au
  organization: Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
– sequence: 2
  givenname: Ibrahim M
  surname: El-Deeb
  fullname: El-Deeb, Ibrahim M
  organization: Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
– sequence: 3
  givenname: Yaramah M
  surname: Zalucki
  fullname: Zalucki, Yaramah M
  organization: Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
– sequence: 4
  givenname: Jennifer L
  surname: Edwards
  fullname: Edwards, Jennifer L
  organization: The Center for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital and The Department of Pediatrics, The Ohio State University, Columbus, OH, USA
– sequence: 5
  givenname: Mark J
  surname: Walker
  fullname: Walker, Mark J
  organization: School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia
– sequence: 6
  givenname: Mark
  surname: von Itzstein
  fullname: von Itzstein, Mark
  organization: Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
– sequence: 7
  givenname: Michael P
  surname: Jennings
  fullname: Jennings, Michael P
  email: m.jennings@griffith.edu.au
  organization: Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34450628$$D View this record in MEDLINE/PubMed
BookMark eNp9kbtuFEEQRVvICK8NETnqCCHhwf2cmQ3XlsFIFhCYeNSPmnWbme6hHwFE_IY_gp_iS-hlF0KiUlWdunWle4KOfPCA0HNK3lCy5uf3ypzbL0qzNX2EVlS0pGFkTY_QinAim05IfoxOUronhLSy7Z-gYy6EJC3rV-jnBttYttgob51VGfAYIt5M3-_AzRB__XhIuK7wdfHZ-W0O_s_IugQqwRn-dHHLznbXWAOOsJS4hAQW51A7byHiD-BSgugU3gYfYrwLoACnkgws2ekJdqxXuUQ1VaHsgnem_sxudiYG7ep42aEW0lP0eFRTgmeHeoo-v726vbxubj6-e3-5uWkMl11uqGJSEmqUBDtqApb2jGtmOkvXUtO-o4KbrqOqs6KzvWKcGcMUtSCFbkfNT9Grve4Sw9cCKQ-zq36nSXkIJQ1Mti0RrBOioq_3aPWaUoRxWKKbVfw2UDLs8hlqPsMhn0q_OAgXPYP9x_4NpAIv90Aoy3-VfgOpOqDJ
CitedBy_id crossref_primary_10_1128_aac_02318_21
crossref_primary_10_3390_antibiotics12091382
crossref_primary_10_1093_femsre_fuae009
crossref_primary_10_1126_sciadv_adg4205
crossref_primary_10_1128_msphere_00362_22
Cites_doi 10.1128/IAI.68.9.5354-5363.2000
10.1128/ecosalplus.ESP-0005-2018
10.1128/JB.187.15.5387-5396.2005
10.1093/jac/dkw288
10.1128/AAC.41.8.1738
10.1016/S1474-4422(14)70262-5
10.1016/S0091-7435(02)00058-0
10.1093/jac/dkz339
10.1128/mBio.02391-18
10.1016/j.bbamem.2006.03.030
10.3389/fmicb.2018.01922
10.3390/ph9010013
10.1111/j.1365-2958.2006.05478.x
10.1097/OLQ.0000000000000602
10.1016/S1474-4422(08)70167-4
10.1073/pnas.160261497
10.1016/0923-2508(94)90083-3
10.1021/acs.jproteome.5b00938
10.1021/acsinfecdis.9b00307
10.1093/cid/ciu213
10.1128/IAI.68.3.1664-1671.2000
10.1126/scitranslmed.abb3791
10.3109/1040841X.2015.1105782
10.1038/s41572-019-0128-6
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021
The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021
– notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1093/jac/dkab291
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1460-2091
EndPage 2853
ExternalDocumentID 10_1093_jac_dkab291
34450628
10.1093/jac/dkab291
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
6.Y
70D
AABZA
AACZT
AAJKP
AAJQQ
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABPTD
ABQLI
ABQNK
ABQTQ
ABSAR
ABSMQ
ABWST
ABXVV
ABZBJ
ACCCW
ACFRR
ACGFO
ACGFS
ACIWK
ACMRT
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ACZBC
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEJOX
AEKPW
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFRAH
AFSHK
AFXAL
AFXEN
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AI.
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APJGH
APWMN
AQDSO
AQKUS
ASPBG
ATGXG
ATTQO
AVNTJ
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
BZKNY
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
IOX
J21
J5H
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MBLQV
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBS
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
QBD
R44
RD5
RHF
RNI
ROL
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TMA
TR2
UCJ
VH1
W8F
WOQ
X7H
Y6R
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZXP
~91
~A~
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c357t-1a25501ca5edfb0ed1823b2c7d195b187143c771a7d47d8a232cc2a1de54b6fb3
ISSN 0305-7453
IngestDate Fri Aug 16 07:49:52 EDT 2024
Thu Sep 12 20:00:35 EDT 2024
Wed Oct 16 00:43:32 EDT 2024
Wed Aug 28 03:19:54 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c357t-1a25501ca5edfb0ed1823b2c7d195b187143c771a7d47d8a232cc2a1de54b6fb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/jac/article-pdf/76/11/2850/40641263/dkab291.pdf
PMID 34450628
PQID 2566042744
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_2566042744
crossref_primary_10_1093_jac_dkab291
pubmed_primary_34450628
oup_primary_10_1093_jac_dkab291
PublicationCentury 2000
PublicationDate 2021-10-11
PublicationDateYYYYMMDD 2021-10-11
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-10-11
  day: 11
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of antimicrobial chemotherapy
PublicationTitleAlternate J Antimicrob Chemother
PublicationYear 2021
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Chen (2021101808551757000_dkab291-B3) 2017; 44
Peak (2021101808551757000_dkab291-B13) 2016; 15
Stull (2021101808551757000_dkab291-B23) 2018; 8
Durr (2021101808551757000_dkab291-B15) 2006; 1758
Jen (2021101808551757000_dkab291-B9) 2020; 6
Bohlmann (2021101808551757000_dkab291-B7) 2018; 9
De Oliveira (2021101808551757000_dkab291-B12) 2020; 12
Edwards (2021101808551757000_dkab291-B4) 2016; 42
Unemo (2021101808551757000_dkab291-B1) 2019; 5
Tzeng (2021101808551757000_dkab291-B11) 2005; 187
(2021101808551757000_dkab291-B24) 2015; 14
Kahler (2021101808551757000_dkab291-B8) 2018; 9
John (2021101808551757000_dkab291-B17) 2019; 74
Steinberg (2021101808551757000_dkab291-B19) 1997; 41
Tanphaichitr (2021101808551757000_dkab291-B16) 2016; 9
Forst (2021101808551757000_dkab291-B20) 1994; 145
Farley (2021101808551757000_dkab291-B2) 2003; 36
Schwartz (2021101808551757000_dkab291-B21) 2000; 97
Unemo (2021101808551757000_dkab291-B5) 2016; 71
Lannfelt (2021101808551757000_dkab291-B6) 2008; 7
Edwards (2021101808551757000_dkab291-B14) 2000; 68
Lysenko (2021101808551757000_dkab291-B18) 2000; 68
Nation (2021101808551757000_dkab291-B10) 2014; 59
Seib (2021101808551757000_dkab291-B22) 2007; 63
References_xml – volume: 68
  start-page: 5354
  year: 2000
  ident: 2021101808551757000_dkab291-B14
  article-title: Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells
  publication-title: Infect Immun
  doi: 10.1128/IAI.68.9.5354-5363.2000
  contributor:
    fullname: Edwards
– volume: 8
  year: 2018
  ident: 2021101808551757000_dkab291-B23
  article-title: Periplasmic chaperones and prolyl isomerases
  publication-title: EcoSal Plus
  doi: 10.1128/ecosalplus.ESP-0005-2018
  contributor:
    fullname: Stull
– volume: 187
  start-page: 5387
  year: 2005
  ident: 2021101808551757000_dkab291-B11
  article-title: Cationic antimicrobial peptide resistance in Neisseria meningitidis
  publication-title: J Bacteriol
  doi: 10.1128/JB.187.15.5387-5396.2005
  contributor:
    fullname: Tzeng
– volume: 71
  start-page: 3096
  year: 2016
  ident: 2021101808551757000_dkab291-B5
  article-title: The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkw288
  contributor:
    fullname: Unemo
– volume: 41
  start-page: 1738
  year: 1997
  ident: 2021101808551757000_dkab291-B19
  article-title: Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.41.8.1738
  contributor:
    fullname: Steinberg
– volume: 14
  start-page: 39
  year: 2015
  ident: 2021101808551757000_dkab291-B24
  article-title: Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(14)70262-5
– volume: 36
  start-page: 502
  year: 2003
  ident: 2021101808551757000_dkab291-B2
  article-title: Asymptomatic sexually transmitted diseases: the case for screening
  publication-title: Prev Med
  doi: 10.1016/S0091-7435(02)00058-0
  contributor:
    fullname: Farley
– volume: 74
  start-page: 3245
  year: 2019
  ident: 2021101808551757000_dkab291-B17
  article-title: Cationic cell-penetrating peptide is bactericidal against Neisseria gonorrhoeae
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkz339
  contributor:
    fullname: John
– volume: 9
  start-page: e02391-18
  year: 2018
  ident: 2021101808551757000_dkab291-B7
  article-title: Chemical synergy between ionophore PBT2 and zinc reverses antibiotic resistance
  publication-title: MBio
  doi: 10.1128/mBio.02391-18
  contributor:
    fullname: Bohlmann
– volume: 1758
  start-page: 1408
  year: 2006
  ident: 2021101808551757000_dkab291-B15
  article-title: LL-37, the only human member of the cathelicidin family of antimicrobial peptides
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamem.2006.03.030
  contributor:
    fullname: Durr
– volume: 9
  start-page: 1922
  year: 2018
  ident: 2021101808551757000_dkab291-B8
  article-title: Structure-function relationships of the neisserial EptA enzyme responsible for phosphoethanolamine decoration of lipid A: rationale for drug targeting
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2018.01922
  contributor:
    fullname: Kahler
– volume: 9
  start-page: 13
  year: 2016
  ident: 2021101808551757000_dkab291-B16
  article-title: Potential use of antimicrobial peptides as vaginal spermicides/microbicides
  publication-title: Pharmaceuticals (Basel)
  doi: 10.3390/ph9010013
  contributor:
    fullname: Tanphaichitr
– volume: 63
  start-page: 54
  year: 2007
  ident: 2021101808551757000_dkab291-B22
  article-title: Characterization of the OxyR regulon of Neisseria gonorrhoeae
  publication-title: Mol Microbiol
  doi: 10.1111/j.1365-2958.2006.05478.x
  contributor:
    fullname: Seib
– volume: 44
  start-page: 359
  year: 2017
  ident: 2021101808551757000_dkab291-B3
  article-title: Retrospective review of gonococcal and chlamydial cases of epididymitis at 2 Canadian sexually transmitted infection clinics, 2004-2014
  publication-title: Sex Transm Dis
  doi: 10.1097/OLQ.0000000000000602
  contributor:
    fullname: Chen
– volume: 7
  start-page: 779
  year: 2008
  ident: 2021101808551757000_dkab291-B6
  article-title: Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(08)70167-4
  contributor:
    fullname: Lannfelt
– volume: 97
  start-page: 9009
  year: 2000
  ident: 2021101808551757000_dkab291-B21
  article-title: The cysteine desulfurase, IscS, has a major role in in vivo Fe-S cluster formation in Escherichia coli
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.160261497
  contributor:
    fullname: Schwartz
– volume: 145
  start-page: 363
  year: 1994
  ident: 2021101808551757000_dkab291-B20
  article-title: Signal transduction by the EnvZ-OmpR phosphotransfer system in bacteria
  publication-title: Res Microbiol
  doi: 10.1016/0923-2508(94)90083-3
  contributor:
    fullname: Forst
– volume: 15
  start-page: 2356
  year: 2016
  ident: 2021101808551757000_dkab291-B13
  article-title: Neisseria meningitidis lacking the major porins PorA and PorB is viable and modulates apoptosis and the oxidative burst of neutrophils
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.5b00938
  contributor:
    fullname: Peak
– volume: 6
  start-page: 50
  year: 2020
  ident: 2021101808551757000_dkab291-B9
  article-title: Neisseria gonorrhoeae becomes susceptible to polymyxin B and colistin in the presence of PBT2
  publication-title: ACS Infect Dis
  doi: 10.1021/acsinfecdis.9b00307
  contributor:
    fullname: Jen
– volume: 59
  start-page: 88
  year: 2014
  ident: 2021101808551757000_dkab291-B10
  article-title: Colistin and polymyxin B: peas in a pod, or chalk and cheese?
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu213
  contributor:
    fullname: Nation
– volume: 68
  start-page: 1664
  year: 2000
  ident: 2021101808551757000_dkab291-B18
  article-title: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract
  publication-title: Infect Immun
  doi: 10.1128/IAI.68.3.1664-1671.2000
  contributor:
    fullname: Lysenko
– volume: 12
  start-page: eabb3791
  year: 2020
  ident: 2021101808551757000_dkab291-B12
  article-title: Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.abb3791
  contributor:
    fullname: De Oliveira
– volume: 42
  start-page: 928
  year: 2016
  ident: 2021101808551757000_dkab291-B4
  article-title: Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development
  publication-title: Crit Rev Microbiol
  doi: 10.3109/1040841X.2015.1105782
  contributor:
    fullname: Edwards
– volume: 5
  start-page: 79
  year: 2019
  ident: 2021101808551757000_dkab291-B1
  article-title: Gonorrhoea
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/s41572-019-0128-6
  contributor:
    fullname: Unemo
SSID ssj0006568
Score 2.441646
Snippet Abstract Background Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the...
Neisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence of MDR N....
BACKGROUNDNeisseria gonorrhoeae is a Gram-negative bacterial pathogen that causes gonorrhoea. No vaccine is available to prevent gonorrhoea and the emergence...
SourceID proquest
crossref
pubmed
oup
SourceType Aggregation Database
Index Database
Publisher
StartPage 2850
SubjectTerms Alzheimer Disease - drug therapy
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antimicrobial Cationic Peptides - pharmacology
Antimicrobial Peptides
Gonorrhea - drug therapy
Humans
Huntington Disease - drug therapy
Microbial Sensitivity Tests
Neisseria gonorrhoeae
Pharmaceutical Preparations
Proteomics
Title A drug candidate for Alzheimer’s and Huntington’s disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides
URI https://www.ncbi.nlm.nih.gov/pubmed/34450628
https://search.proquest.com/docview/2566042744
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB61RUJcUClbWQep6iVxG9vj7RggKCAV9ZBKhYs145k0hsSuvBzaE3-DH8Gf4pfwZvEStWW7OLH9PFb0fXnz3sxbENojoXDCkIcWuMrgoDiUWlHi-5ZgHmhMZs9tXyYKH330pyfkw6l3urG53Ytaqit2kFxem1fyP6jCNcBVZsn-A7LtoHABvgO-cASE4fhXGI8HvKjPZOAWT6XnrmIGx8vLhUhlUxQTxxDpMsxT3RRC2nrdDbM_o2zJ1zNHfkq1yGQzlXPAIC_BIAXztFAd50Alqu37lA7O8iwvikUuqBiUdamCY2QSFsiqWqGy7Ihe7JX1YKt0laqKTzLvS4pyE7p41SxeFwZKrUyOWBfsI4zJLTgdTAZWu847WVpvhVAbTO8ZKNF01a31fqbLOtEtuj_Rgq7oorunG1eX_WAfk4xhlkMcFY9nd8shN6RZ9rQqKDgrILpC8YHQWp_4IyCWbhvWTAu6LU1Df7uv5ENdK9cYDHDqXjsZ6UJdX2gCR_6VMse8YL2-9w2Sm-iWE0SeKlw87Tw6X2d3tr_CpJzCAIfw-KF5eM3IWkvcvOI_KTtqto3uGqTxWLP5HtoQ2Q66fWRCPHbQ_rEupn4xxLMuN7Ac4n183JVZv7iPfoyxZD9u2Y8BE9yy_-e37yWGW7jjvbpkGD_Eku9D-TRmAndsx1WONdtxy3bcYzvusV3KGrbjhu14jcC4YfsDdPJuMnsztUzzEStxvaCybArO9shOqCf4nI0EB0fcZU4ScDvymB0G4GgkQWDTgJOAhxQ8kyRxqM2FR5g_Z-5DtJXlmXiMMPeJlPS4TQgB5JgXsUiMOBu5IooY2UV7DVrxua4xE-vYEDcGUGMD6i56CUj-XuJVg3IMs4Tc-qOZyOsyBsfGl111CLzskYa_HcglxJOZ1E_-OP5TdKf7yz1DW1VRi-dgk1fshWLpL9t86TM
link.rule.ids 315,786,790,27955,27956
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+drug+candidate+for+Alzheimer%E2%80%99s+and+Huntington%E2%80%99s+disease%2C+PBT2%2C+can+be+repurposed+to+render+Neisseria+gonorrhoeae+susceptible+to+natural+cationic+antimicrobial+peptides&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Jen%2C+Freda+E+-C&rft.au=El-Deeb%2C+Ibrahim+M&rft.au=Zalucki%2C+Yaramah+M&rft.au=Edwards%2C+Jennifer+L&rft.date=2021-10-11&rft.pub=Oxford+University+Press&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=76&rft.issue=11&rft.spage=2850&rft.epage=2853&rft_id=info:doi/10.1093%2Fjac%2Fdkab291&rft.externalDocID=10.1093%2Fjac%2Fdkab291
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon